Best Building Product Companies For 2014

Quanex Building Products (NYSE: NX  ) reported earnings on June 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended April 30 (Q2), Quanex Building Products beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share dropped.

Margins increased across the board.

Revenue details
Quanex Building Products reported revenue of $232.5 million. The seven analysts polled by S&P Capital IQ expected revenue of $224.8 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $194.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

Best Building Product Companies For 2014: Investors Title Company(ITIC)

Investors Title Company, through its subsidiaries, provides title insurance to residential, institutional, commercial, and industrial properties. It underwrites land title insurance for owners and mortgagees as a primary insurer; and offers the reinsurance of title insurance risks to other title insurance companies. The company also provides tax-deferred real property exchange services, as well as serves as an exchange accommodation titleholder and holds property for exchangers in reverse exchange transactions; offers investment management and trust services to individuals, companies, banks, and trusts; and provides consulting services to title insurance agencies. Investors Title Company serves various customers in the residential and commercial market sectors of the real estate industry. It issues title insurance policies primarily through approved attorneys from underwriting offices, as well as through independent issuing agents in 24 states and the District of Columbia, the United States. The company was founded in 1972 and is headquartered in Chapel Hill, North Carolina.

Best Building Product Companies For 2014: Navidea Biopharmaceuticals Inc (NAVB.A)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

< p>

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-c enter Phase II trial and three multi-center Phase II trial! s ! involving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has b een studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Top 5 Oil Stocks To Watch Right Now: Olympus Pacific Minerals Inc(OYM.TO)

Olympus Pacific Minerals Inc. engages in the acquisition, exploration, development, mining, and reinstatement of gold bearing properties in southeast Asia. The company produces and sells primarily gold and by-products, such as silver. Its principal properties include the Bong Mieu Gold property and the Phuoc Son Gold property located in central Vietnam; the Bau Gold property located in central Malaysia; and the Capcapo Gold Property located in the northern Philippines. The company was formerly known as Olympus Holdings Ltd. and changed its name to Olympus Pacific Minerals Inc. in November 1996. Olympus Pacific Minerals Inc. was incorporated in 1951 and is based in Toronto, Canada.

Best Building Product Companies For 2014: Genesis Land Devel Com Npv (GDC.TO)

Genesis Land Development Corp., a real estate development company, together with its subsidiaries, engages in the acquisition, development, subdivision, construction, sale, and leasing of land, residential lots and homes, and commercial properties in Alberta and British Columbia. It operates in four divisions: Land Development, Single-Family Home Building, Multi-Family Home Building, and Commercial Development. The Land Development division principally develops residential lots in the cities of Calgary, Airdrie, Edmonton, and Cochrane, Alberta; and in Prince George, Kamloops, and Radium, British Columbia. The Single-Family Home Building division builds and sells single-family homes. The Multi-Family Home Building division builds town homes and apartment complexes. The Commercial division engages in selling, leasing, and developing commercial, industrial, and office properties. The company was formerly known as Genesis Capital Corp. and changed its name to Genesis Land Deve lopment Corp. in October 1998. Genesis Land Development Corp. was founded in 1997 and is headquartered in Calgary, Canada.

Best Building Product Companies For 2014: Pelangio Exploration Inc (PX.V)

Pelangio Exploration Inc., a junior gold exploration company, engages in the acquisition, exploration, and development of mineral property interests. The company has a 100% interest in the Obuasi Property that covers approximately 290 square kilometers; and the Manfo Property, which covers approximately 100 square kilometers in Ghana, West Africa. It also holds a 100% interest in the Birch Lake and Poirier Gold properties in Ontario, Canada, as well as has interests in various properties located in Ontario and Quebec. Pelangio Exploration Inc. was incorporated in 2008 and is headquartered in Milton, Canada.